<DOC>
	<DOC>NCT01457573</DOC>
	<brief_summary>A single center, pilot trial with combination therapy of tamsulosin and solifenacin in 20 men with symptomatic lower urinary tract symptoms (LUTS). Subjects will be evaluated at baseline, 1, 2, and 3 months for urinary NGF, urine creatinine, NGF/CR ratio and patient reported outcomes.</brief_summary>
	<brief_title>Pilot Trial Of Urinary Nerve Growth Factor (NGF) As Biomarker for Male Lower Urinary Tract Symptoms</brief_title>
	<detailed_description />
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Men &gt; 50 years old with symptomatic LUTS (clinical BPH) IPSS &gt; 8 PSA &lt; 10 (negative biopsies within 6 months for any agespecific PSA elevation suspicious for prostate carcinoma) Post void residual urine &lt; 150 mls Urinary Flow rate &gt; 15 mL/sec Neurogenic bladder Urinary tract infection, Urinary stone(s), Urinary tract tumor Radiation therapy for urologic malignancy or prostate surgery; radiation to pelvic, colon, rectum, prostate, bladder, uterus or ovaries Alpha blocker therapy or anticholinergic therapy within 3 months of entry or 5 alpha reductase therapy within 18 months. History of cataracts with planned surgery</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>